Compound class:
Synthetic organic
Comment: STK16-IN-1 is a selective inhibitor of serine/threonine kinase 16 (STK16) that can be used as a pharmacological tool to investigate the biological functions of STK16 [2]. It is compound 219 in a 2010 patent claiming mTOR inhibitors [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Gray N, Chang JW, Zhang J, Thoreen CC, Kang SWA, Sabatini DM, Liu Q. (2010)
Soluble mtor complexes and modulators thereof. Patent number: WO2010044885. Assignee: Whitehead Institute For Biomedical Research, Dana-Farber Cancer Institute, Inc.. Priority date: 17/10/2008. Publication date: 22/04/2010. |
2. Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W et al.. (2016)
Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem Biol, 11 (6): 1537-43. [PMID:27082499] |